JP2019532011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532011A5 JP2019532011A5 JP2018506309A JP2018506309A JP2019532011A5 JP 2019532011 A5 JP2019532011 A5 JP 2019532011A5 JP 2018506309 A JP2018506309 A JP 2018506309A JP 2018506309 A JP2018506309 A JP 2018506309A JP 2019532011 A5 JP2019532011 A5 JP 2019532011A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- therapeutic agent
- patient
- chromosomal
- flt3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 45
- 229940124597 therapeutic agent Drugs 0.000 claims 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 25
- 230000002062 proliferating effect Effects 0.000 claims 25
- 230000005856 abnormality Effects 0.000 claims 23
- 230000002068 genetic effect Effects 0.000 claims 23
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 22
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 22
- 208000035475 disorder Diseases 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 9
- 102000005962 receptors Human genes 0.000 claims 9
- 230000002759 chromosomal effect Effects 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 208000032839 leukemia Diseases 0.000 claims 8
- 230000002074 deregulated effect Effects 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 6
- 230000000306 recurrent effect Effects 0.000 claims 6
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 claims 5
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims 5
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims 5
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 claims 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 claims 5
- 108700020467 WT1 Proteins 0.000 claims 5
- 101150084041 WT1 gene Proteins 0.000 claims 5
- 230000037437 driver mutation Effects 0.000 claims 5
- 230000005861 gene abnormality Effects 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 5
- 102100035886 Adenine DNA glycosylase Human genes 0.000 claims 4
- 102100021247 BCL-6 corepressor Human genes 0.000 claims 4
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims 4
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims 4
- 102000049320 CD36 Human genes 0.000 claims 4
- 108010045374 CD36 Antigens Proteins 0.000 claims 4
- 206010008805 Chromosomal abnormalities Diseases 0.000 claims 4
- 206010061764 Chromosomal deletion Diseases 0.000 claims 4
- 208000031404 Chromosome Aberrations Diseases 0.000 claims 4
- 208000036086 Chromosome Duplication Diseases 0.000 claims 4
- 208000016718 Chromosome Inversion Diseases 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 4
- 102100035595 Cohesin subunit SA-2 Human genes 0.000 claims 4
- 108700031843 GRB7 Adaptor Proteins 0.000 claims 4
- 101150052409 GRB7 gene Proteins 0.000 claims 4
- 102100030708 GTPase KRas Human genes 0.000 claims 4
- 102100039788 GTPase NRas Human genes 0.000 claims 4
- 208000034951 Genetic Translocation Diseases 0.000 claims 4
- 102100033107 Growth factor receptor-bound protein 7 Human genes 0.000 claims 4
- 101001000351 Homo sapiens Adenine DNA glycosylase Proteins 0.000 claims 4
- 101100165236 Homo sapiens BCOR gene Proteins 0.000 claims 4
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims 4
- 101000642968 Homo sapiens Cohesin subunit SA-2 Proteins 0.000 claims 4
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 4
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 4
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims 4
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 4
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims 4
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims 4
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 claims 4
- 101000654718 Homo sapiens SET-binding protein Proteins 0.000 claims 4
- 101000587430 Homo sapiens Serine/arginine-rich splicing factor 2 Proteins 0.000 claims 4
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 claims 4
- 101000808799 Homo sapiens Splicing factor U2AF 35 kDa subunit Proteins 0.000 claims 4
- 101000837401 Homo sapiens T-cell leukemia/lymphoma protein 1A Proteins 0.000 claims 4
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 claims 4
- 101000762128 Homo sapiens Tumor suppressor candidate 3 Proteins 0.000 claims 4
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 4
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims 4
- 101000658084 Homo sapiens U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Proteins 0.000 claims 4
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims 4
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 4
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims 4
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 4
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims 4
- 102100025372 Nuclear pore complex protein Nup98-Nup96 Human genes 0.000 claims 4
- 102100022678 Nucleophosmin Human genes 0.000 claims 4
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 claims 4
- 102100032741 SET-binding protein Human genes 0.000 claims 4
- 101100494218 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BRP1 gene Proteins 0.000 claims 4
- 102100029666 Serine/arginine-rich splicing factor 2 Human genes 0.000 claims 4
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 claims 4
- 102100038501 Splicing factor U2AF 35 kDa subunit Human genes 0.000 claims 4
- 102100028676 T-cell leukemia/lymphoma protein 1A Human genes 0.000 claims 4
- 102100039580 Transcription factor ETV6 Human genes 0.000 claims 4
- 208000037280 Trisomy Diseases 0.000 claims 4
- 102100024248 Tumor suppressor candidate 3 Human genes 0.000 claims 4
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 4
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims 4
- 102100035036 U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Human genes 0.000 claims 4
- 102100022748 Wilms tumor protein Human genes 0.000 claims 4
- 208000036878 aneuploidy Diseases 0.000 claims 4
- 231100001075 aneuploidy Toxicity 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 4
- 230000037431 insertion Effects 0.000 claims 4
- 238000003780 insertion Methods 0.000 claims 4
- 208000030454 monosomy Diseases 0.000 claims 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims 4
- 108010054452 nuclear pore complex protein 98 Proteins 0.000 claims 4
- 238000010837 poor prognosis Methods 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 3
- -1 MLL Proteins 0.000 claims 3
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 3
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000002327 eosinophilic effect Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 1
- 201000009928 Patau syndrome Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 206010044686 Trisomy 13 Diseases 0.000 claims 1
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 claims 1
- 206010053871 Trisomy 8 Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 229960005260 amiodarone Drugs 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229960003413 dolasetron Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 1
- 229960004770 esomeprazole Drugs 0.000 claims 1
- 238000009093 first-line therapy Methods 0.000 claims 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004884 fluconazole Drugs 0.000 claims 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical group C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 1
- 229960003727 granisetron Drugs 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960004130 itraconazole Drugs 0.000 claims 1
- 229960004125 ketoconazole Drugs 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960002509 miconazole Drugs 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- 210000001167 myeloblast Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 claims 1
- 229960005019 pantoprazole Drugs 0.000 claims 1
- 229960004448 pentamidine Drugs 0.000 claims 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 229960001589 posaconazole Drugs 0.000 claims 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 1
- 208000034298 trisomy chromosome 8 Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022031616A JP7536320B2 (ja) | 2016-11-02 | 2022-03-02 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
| JP2024064106A JP2024096859A (ja) | 2016-11-02 | 2024-04-11 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416475P | 2016-11-02 | 2016-11-02 | |
| US62/416,475 | 2016-11-02 | ||
| PCT/US2017/059377 WO2018085292A1 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
| US15/799,684 | 2017-10-31 | ||
| US15/799,684 US11078541B2 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031616A Division JP7536320B2 (ja) | 2016-11-02 | 2022-03-02 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532011A JP2019532011A (ja) | 2019-11-07 |
| JP2019532011A5 true JP2019532011A5 (https=) | 2020-06-25 |
Family
ID=62020370
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506309A Pending JP2019532011A (ja) | 2016-11-02 | 2017-10-31 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
| JP2022031616A Active JP7536320B2 (ja) | 2016-11-02 | 2022-03-02 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
| JP2024064106A Withdrawn JP2024096859A (ja) | 2016-11-02 | 2024-04-11 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031616A Active JP7536320B2 (ja) | 2016-11-02 | 2022-03-02 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
| JP2024064106A Withdrawn JP2024096859A (ja) | 2016-11-02 | 2024-04-11 | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11078541B2 (https=) |
| EP (1) | EP3359155A4 (https=) |
| JP (3) | JP2019532011A (https=) |
| KR (2) | KR20200079351A (https=) |
| CN (1) | CN108778276A (https=) |
| AU (1) | AU2017353925A1 (https=) |
| BR (1) | BR112019008762A2 (https=) |
| CA (1) | CA3024012A1 (https=) |
| CL (1) | CL2019001208A1 (https=) |
| CO (1) | CO2019005466A2 (https=) |
| EA (1) | EA201991078A1 (https=) |
| HK (1) | HK1257195A1 (https=) |
| IL (1) | IL266303A (https=) |
| MX (1) | MX2019005008A (https=) |
| PE (1) | PE20191238A1 (https=) |
| PH (1) | PH12019500965A1 (https=) |
| SG (1) | SG11201903889TA (https=) |
| WO (1) | WO2018085292A1 (https=) |
| ZA (1) | ZA201903089B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12534764B2 (en) | 2016-11-02 | 2026-01-27 | Arog Pharmaceuticals, Inc. | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
| BR112019008762A2 (pt) | 2016-11-02 | 2019-07-16 | Arog Pharmaceuticals, Inc. | método para o tratamento de um distúrbio proliferativo mutado em flt3 |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| US12268690B2 (en) | 2018-07-27 | 2025-04-08 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
| EP3856173A4 (en) * | 2018-09-26 | 2022-07-06 | Kura Oncology, Inc. | TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS |
| CN109678849A (zh) * | 2019-01-16 | 2019-04-26 | 北京悦康科创医药科技股份有限公司 | 一种抗癌药物的制备方法 |
| US11471451B2 (en) * | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
| CN110531016B (zh) * | 2019-09-05 | 2021-08-31 | 合肥诺明药物安全研究有限公司 | 一种hyml-122血药浓度定量分析方法 |
| JP2023536068A (ja) * | 2020-07-20 | 2023-08-23 | アログ・ファーマシューティカルズ・インコーポレイテッド | クレノラニブの結晶形態およびそれを用いる方法 |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US11524006B2 (en) | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
| CN112921091B (zh) * | 2021-03-16 | 2022-01-21 | 南京先声医学检验实验室有限公司 | Flt3基因突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
| JP2023063189A (ja) * | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
| CN115141886B (zh) * | 2022-06-28 | 2023-06-06 | 厦门艾德生物医药科技股份有限公司 | 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| WO1999016755A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| AU2002226877B2 (en) | 2000-10-17 | 2006-01-12 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US7101884B2 (en) | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| ES2269793T3 (es) | 2001-10-30 | 2007-04-01 | Novartis Ag | Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3. |
| ATE302771T1 (de) | 2001-12-27 | 2005-09-15 | Theravance Inc | Indolinon-derivative als protein-kinasehemmer |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| MXPA05001804A (es) | 2002-08-14 | 2005-05-27 | Vertex Pharma | Inhibidores de proteinas cinasas y usos de los mismos. |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| AU2003280599A1 (en) | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| AU2003290699B2 (en) | 2002-11-13 | 2009-08-27 | Novartis Vaccines And Diagnostics, Inc. | Methods of treating cancer and related methods |
| CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
| DK1641780T3 (da) | 2003-06-24 | 2009-02-02 | Pfizer Prod Inc | Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater |
| US8999638B2 (en) * | 2009-04-06 | 2015-04-07 | Vanda Pharmaceuticals, Inc. | Method of treatment based on polymorphisms of the KCNQ1 gene |
| JP2015512630A (ja) * | 2012-03-12 | 2015-04-30 | メモリアル スローン−ケタリング キャンサー センター | 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物 |
| TWI599356B (zh) | 2012-09-26 | 2017-09-21 | 安羅格製藥有限責任公司 | 抑制突變型ｃ－ｋｉｔ的方法 |
| BR112015016282A2 (en) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| BR112019008762A2 (pt) | 2016-11-02 | 2019-07-16 | Arog Pharmaceuticals, Inc. | método para o tratamento de um distúrbio proliferativo mutado em flt3 |
-
2017
- 2017-10-31 BR BR112019008762-1A patent/BR112019008762A2/pt not_active Application Discontinuation
- 2017-10-31 PE PE2019000923A patent/PE20191238A1/es unknown
- 2017-10-31 SG SG11201903889TA patent/SG11201903889TA/en unknown
- 2017-10-31 MX MX2019005008A patent/MX2019005008A/es unknown
- 2017-10-31 EA EA201991078A patent/EA201991078A1/ru unknown
- 2017-10-31 WO PCT/US2017/059377 patent/WO2018085292A1/en not_active Ceased
- 2017-10-31 EP EP17866388.6A patent/EP3359155A4/en active Pending
- 2017-10-31 US US15/799,684 patent/US11078541B2/en active Active
- 2017-10-31 KR KR1020207018302A patent/KR20200079351A/ko not_active Ceased
- 2017-10-31 CA CA3024012A patent/CA3024012A1/en active Pending
- 2017-10-31 CN CN201780016669.1A patent/CN108778276A/zh active Pending
- 2017-10-31 HK HK18116172.6A patent/HK1257195A1/zh unknown
- 2017-10-31 JP JP2018506309A patent/JP2019532011A/ja active Pending
- 2017-10-31 KR KR1020187016693A patent/KR20180074792A/ko not_active Ceased
- 2017-10-31 AU AU2017353925A patent/AU2017353925A1/en not_active Abandoned
-
2019
- 2019-04-29 IL IL266303A patent/IL266303A/en unknown
- 2019-04-30 PH PH12019500965A patent/PH12019500965A1/en unknown
- 2019-05-02 CL CL2019001208A patent/CL2019001208A1/es unknown
- 2019-05-17 ZA ZA2019/03089A patent/ZA201903089B/en unknown
- 2019-05-24 CO CONC2019/0005466A patent/CO2019005466A2/es unknown
-
2021
- 2021-06-23 US US17/355,468 patent/US12404555B2/en active Active
-
2022
- 2022-03-02 JP JP2022031616A patent/JP7536320B2/ja active Active
-
2024
- 2024-04-11 JP JP2024064106A patent/JP2024096859A/ja not_active Withdrawn
-
2025
- 2025-06-11 US US19/234,777 patent/US20250305063A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532011A5 (https=) | ||
| JP2022071099A5 (https=) | ||
| JP7536320B2 (ja) | Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ | |
| Chen et al. | Clinical perspective of afatinib in non-small cell lung cancer | |
| WO2023190748A1 (ja) | 腫瘍治療用医薬組成物 | |
| JP2014065696A5 (https=) | ||
| JP2014097929A5 (https=) | ||
| EP3585389A1 (en) | Treatment of egfr-driven cancer with fewer side effects | |
| JP7504097B2 (ja) | Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法 | |
| US20210196719A1 (en) | Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseases | |
| CN105338980A (zh) | 药物组合 | |
| WO2015084804A1 (en) | Combination of mdm2 inhibitor and braf inhibitor and their use | |
| JP2025540925A (ja) | 癌の治療におけるアゼノセルチブの断続的投与レジメン | |
| EP3928780A1 (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| JP2016106092A (ja) | 組合せ | |
| JP2023063189A5 (https=) | ||
| WO2025033367A1 (ja) | 抗腫瘍剤併用療法 | |
| WO2020239051A1 (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2016104765A (ja) | 組合せ | |
| Alaa El-Deen et al. | AML and FLT3: an update on FDA-approved or under review kinase inhibitors targeting FLT3 kinase | |
| JP2022549272A (ja) | Ｅｇｆｒ阻害剤とｃｄｋ４／６阻害剤の組み合わせを用いたｅｇｆｒ変異に関連する癌の治療 | |
| Spira et al. | EP08. 02-019 phase 1/2 study of BLU-701, a highly selective EGFR inhibitor, in patients with EGFR-mutant Non-Small cell lung cancer | |
| JP7497353B2 (ja) | Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法 | |
| Alshehri et al. | Personalized Medicine Approaches for Pediatric Leukemia: Developing Targeted Therapies Based on Genetic Profiles | |
| Betancor-Fernández | BRCAness and breast cancer: BRCAness y cáncer de mama |